ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced that ...
The adaptive Phase II/III study is using a master protocol to evaluate multiple therapies with a shared control.
The trial is evaluating VIR-5500 with an androgen receptor pathway inhibitor in early-line mCRPC and mHSPC.
According to a study published by The Journal of Pharmacology and Experimental Therapeutics. cannabinoid compounds may help ...